R
Replimune
Biotech & Life Sciences · Woburn, United States · Founded 2015 · IPO 2018
Develops immunotherapies for cancer treatment MoreLess
Replimune is at the forefront of developing advanced cancer treatments through oncolytic immunotherapies. These innovative therapies use engineered viruses to selectively infect and destroy cancer cells while simultaneously stimulating a robust immune response against tumors. By combining multiple mechanisms of action, Replimune's treatments aim to enhance the effectiveness of existing immune checkpoint inhibitors, positioning their approach as a critical component in the evolving landscape of immuno-oncology.
Replimune primarily serves patients battling various forms of cancer, working closely with healthcare providers and research institutions. The company operates within the highly specialized and competitive biotechnology sector, focusing on the development and commercialization of novel cancer therapies.
Replimune's business model revolves around the research, development, and clinical testing of its proprietary oncolytic immunotherapies. Revenue generation is anticipated through partnerships, licensing agreements, and eventual sales of approved therapies. The company invests heavily in clinical trials to validate the efficacy and safety of its treatments, aiming to bring transformative cancer therapies to market.
Keywords: oncolytic immunotherapy, cancer treatment, viral therapy, immune response, biotechnology, clinical trials, immuno-oncology, healthcare innovation, therapeutic development, cancer research.
Company overview
Replimune company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2015
- Headquarters
- Woburn, United States
- Employees
- 352
- Open positions
- 36
- Dealroom signal
- 62.3
Valuation & funding
Replimune funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Jun 2024 | $100M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Dec 2022 | $260M | — | Undisclosed | ↗ |
| POST IPO DEBTDebt | Oct 2022 | $200M | — | Hercules Capital | ↗ |
| POST IPO EQUITYOther financing | Oct 2020 | $250M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Jun 2020 | $100M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Nov 2019 | Undisclosed | ↗ | ||
| IPOOther financing | Jul 2018 | Undisclosed | — | ||
| SERIES BOther financing | Sep 2017 | Cormorant Asset Management · Atlas Venture · Forbion Capital Partners · Omega Funds | — | ||
| SERIES AOther financing | Sep 2015 | Forbion Capital Partners · Atlas Venture · Omega Funds | — | ||
| SEEDOther financing | May 2015 | Undisclosed | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$316M | — |
| 2025 | $0 | — | −$257M | — |
| 2024 | $0 | — | −$229M | — |
| 2023 | $0 | — | −$177M | — |
| 2022 | — | — | −$114M | — |
| 2021 | — | — | −$76M | — |
| 2020 | — | — | −$53M | — |
Growth signals
Replimune website traffic
Latest recorded traffic for Replimune is 14K monthly website visits, down 17.6% over the last three months. Replimune's team declined 23.5% over the past year.
Hiring
Open positions at Replimune
Current openings linked to this company in Dealroom.
Comparisons
Replimune compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Replimune's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Replimune has talent and traffic
team presence
In the news
Latest news about Replimune
Recent press, funding announcements, and product moves mentioning Replimune — open to read from the original sources.
Market sentiment
What the market is saying about Replimune
An AI-synthesized read of the highest-engagement posts about Replimune on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Replimune’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.